Is ORKA or OVID more undervalued in 2026?

CirclFi compares Oruka Therapeutics, Inc. (ORKA) and Ovid Therapeutics Inc. (OVID) using 13 institutional-grade valuation models. ORKA has a Quality of Company score of 4.3/10 while OVID scores 5.3/10.

Which is a better buy — ORKA or OVID?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ORKA and OVID valuations compare?

ORKA at $57.98 and OVID at $2.64 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ORKA vs OVID Valuation Comparison 2026 — Intrinsic Value Analysis

ORKA

Biotechnology

Oruka Therapeutics, Inc.

Quality

4.3

out of 10

Value Trap

SAFE

Price

$57.98

Last close

Models

10/13

Active

OVID

Biotechnology

Ovid Therapeutics Inc.

Quality

5.3

out of 10

Value Trap

LOW

Price

$2.64

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	ORKA Fair Value	ORKA Upside	OVID Fair Value	OVID Upside
Bayesian DCF	Intrinsic	$17.90	-69.1%	$0.80	-69.8%
Earnings Power Value	Intrinsic	$31.09	-55.0%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$5.63	-90.3%	$0.83	-68.7%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ORKA vs OVID — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ORKA vs OVID — Which Stock Is More Undervalued?

OVID scores higher with a 5.3/10 quality rating vs ORKA's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Oruka Therapeutics, Inc. (ORKA) and Ovid Therapeutics Inc. (OVID) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ORKA currently trades at $57.98 with a QOC of 4.3/10, while OVID trades at $2.64 with a QOC of 5.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).